Company intelligence / Profile preview

Cure Ventures

Boston, Massachusetts, United Statescurevc.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Cure Ventures is a Boston-based venture capital firm focused on early-stage investments in life sciences and biotechnology. The firm specializes in company formation around curative technologies for serious diseases. Its inaugural $350 million fund closed in April 2023. Portfolio highlights include Tasca Therapeutics, which develops small molecule therapies targeting cancer-associated proteins[3][5]. The team consists of industry veterans with experience leading successful biotech startups.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibodyCell therapy
Industry: Investors

Partnerships

Regeneron Ventures

Beyond the preview

Go deeper on Cure Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cure Ventures.

Explore the full profile